23316-67-8

Usage

Uses

Used in Pharmaceutical Industry:
2,3,5-Tri-O-benzoyl-beta-D-ribofuranosyl cyanide is used as an intermediate in the synthesis of Tiazofurin (T437200), a potential therapeutic agent for the treatment of cancer. It plays a crucial role in the development of new cancer treatments by contributing to the synthesis of Tiazofurin, which has shown promise in targeting cancer cells and inhibiting their growth.

InChI:InChI=1/C27H21NO7/c28-16-21-23(34-26(30)19-12-6-2-7-13-19)24(35-27(31)20-14-8-3-9-15-20)22(33-21)17-32-25(29)18-10-4-1-5-11-18/h1-15,21-24H,17H2/t21-,22+,23-,24+/m0/s1

Upstream product

• 6974-32-9 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose 
• 7677-24-9 trimethylsilyl cyanide 
• 29706-90-9 β-D-2,3,5-tri-O-benzoylribofuranosyl chloride 
• 52783-53-6 methyl 2,3,3'-tri-O-benzoyl-β-D-apiofuranoside 
• 82225-18-1 3,5-di-O-benzoyl-1,2-O-(1-cyanobenzylidene)-β-ribofuranose 
• 50720-88-2 2,5-anhydro-3,4,6-tri-O-benzoyl-β-D-allose oxime 
• 5517-61-3 methyl 3'-O-benzoyl-β-D-apiofuranoside 
• 107-06-2 1,2-dichloro-ethane 
• 14215-97-5 1-O-acetyl-2,3,5-tri-O-benzoyl-D-ribofuranose 
• 58-63-9 Inosine 
• 98-88-4 benzoyl chloride 
• 22860-91-9 2,3,5-tri-O-benzoyl-D-ribofuranosyl bromide 
• 4099-85-8 ((3aR,4R,6R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol 
• 5517-60-2 methyl 3'-O-benzoyl-2,3-O-isopropylidene-β-D-apiofuranoside 

Downstream Products

• 63128-94-9 (1S)-tri-O-benzoyl-1-(1⁽²⁾H-tetrazol-5-yl)-D-1,4-anhydro-ribitol 
• 39038-02-3 1,3-diphenyl-2-(2′,3′,5′-tri-O-benzoyl-β-D-ribofuranosyl)imidazoline 
• 39050-05-0 2-benzoyloxymethyl-5-(1,3-diphenyl-imidazolidin-2-yl)-furan 
• 30002-87-0 5-O-benzoyl-β-D-ribofuranosyl cyanide 
• 23316-68-9 (2R,3R,4R,5R)-3,4-bis(benzoyloxy)-5-((benzoyloxy)methyl)tetrahydrofuran-2-carboxylic acid 
• 83705-10-6 2,5-anhydro-3,4,6-tri-O-benzoyl-β-D-allonoselenoamide 
• 89873-10-9 2,5-anhydro-3,4,6-tri-O-benzoyl-D-allonamide 
• 89873-11-0 2,5-anhydro-3,4,6-tri-O-benzoyl-D-altronamide 
• 137272-74-3 1-amino-2,5-anhydro-3,4,6-tri-O-benzoyl-1-deoxy-D-allitol 
• 38642-52-3 benzyl 2,3,5-tri-O-benzoyl-D-ribofuranosylthioformimidate hydrochloride 
• 38716-29-9 benzyl 2,5-anhydro-3,4,6-tri-O-benzoyl-D-allonothioimidate hydrochloride 
• 69244-20-8 (2',3',5'-Tri-O-benzoyl-β-D-ribofuranosyl)-ethylthioformimid-hydrochlorid 
• 5097-82-5 1-phenyl-1,2,3,4-tetraaza-3-en-5-one 
• 940-38-5 phenylcarbamoyl azide 

Relevant academic research and scientific papers

A modified synthesis of tiazofurin

An improved synthesis of tiazofurin is described from 1-O-acetyl-2,3,5- tri-O-benzoyl-β-D-ribofuranose.

Action of nitrile hydratase from Rhodococcus rhodochrous IFO 15564 on derivatives of 2,5-anhydro-D-allononitrile

The conversion of 2,5-anhydro-D-allononitrile derivatives by a nitrile hydratase from Rhodococcus rhodochrous IFO 15564 was studied. The activity of the enzyme was strongly effected by the steric bulkiness of the substituents at the 3-position of the substrates, and the corresponding amides were obtained in high yields from the nitriles with free hydroxyl groups at the 3- and 4-positions.

Synthesis and structure-activity relationships of a series of novel thiazoles as inhibitors of aminoacyl-tRNA synthetases

A series of novel aminoacyl adenylate mimics has been prepared and evaluated for their inhibitory activity against aminoacyl-tRNA synthetases. Several of these thiazole derivatives displayed potent and selective enzyme activity against both Gram-positive and Gram-negative bacteria.

COMPOUNDS AS CD73 INHIBITORS

Provided herein are the compounds that are inhibitors of CD73 and are useful in treating CD73-associated diseases or conditions. Compositions containing the compounds are also provided.

Substituted N4-hydroxycytidine derivatives and prodrug thereof for anti-novel coronavirus therapy

The invention relates to a substituted N4-hydroxycytidine derivative with a structure as shown in a formula I, a prodrug and a pharmaceutical composition thereof, and a method of using the compositionfor the treatment of viral infections. The structure of

CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS

The present invention is directed to compounds of formulae (I) and (II) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the tr

CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS

The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS

The present invention is directed to compounds of the formula (I), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPASE

Compounds of general formula IA, IB and IC outlined below, including pharmaceutically acceptable salts, solvates and hydrates thereof. Such compounds and pharmaceutical compositions comprising them may be used in medical conditions involving Ran GTPase.

MUTUAL PRODRUG COMPRISING SHORT CHAIN FATTY ACIDS AND ZEBULARINE OR 1'-CYANO-CYTARABINE FOR CANCER TREATMENT

The present invention provides mutual prodrugs comprising anti-cancer nucleosides and short chain fatty acids; methods for production of the mutual prodrugs; methods of treatment comprising administration of the mutual prodrugs; and pharmaceutical composi